WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East.

Posted: Friday, July 04, 2025

July, 4, 2025 - WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East.

The GEMINI-NSCLC study generates a robust, multi-omic dataset for research in biomarker discovery. The study includes two patient cohorts:
- Patients diagnosed with Stage IV NSCLC receiving standard-of-care first-line checkpoint inhibitor therapy
- Patients with early-stage NSCLC who are candidates for surgery and perioperative treatment

Tempus deploys its comprehensive molecular profiling platform—including solid tumor (xT/xR) and liquid biopsy (xF)—to analyze tumor biology longitudinally in the study. The study focuses on understanding disease progression and treatment response, with emphasis on identifying novel biomarkers and the use of circulating tumor DNA (ctDNA) to monitor MRD.